Muva nje, isiguli esinomdlavuza we-pancreatic osuthuthuke kakhulu esasihlulekile emigqeni eminingi yokwelashwa ngaphambilini sathola ukuncishiswa kwesimila ngemuva kokuthola ukwelashwa kweseli le-KD-496 CAR-T, kanti ukukhululeka okuqinisekisiwe kugcinwe ezinsukwini ezingu-180 ngemuva kokwelashwa.
Njengamanje, kusenezivivinyo eziningi zemitholampilo zobuchwepheshe obusha bokulwa nomdlavuza eShayina ezifuna iziguli. Ukubonisana ngemithi emisha kanye nobuchwepheshe, ungaxhumana noMnyango Wezizwe Ngezizwe Wesibhedlela iBeijing South Region Oncology.
Inombolo yocingo: 4008803716
I-ID ye-WeChat: 17801183037
I-imeyili：myimmnet@163.com
Isiguli, owesifazane oneminyaka engu-73 ubudala, satholakala ngoJulayi 2021 sinekhanda le-pancreatic elihambisana nokuvaleka kwe-bile duct okuphansi. Sahlinzwa i-duodenectomy, lapho kwatholakala khona isisindo esiqinile esingaba ngu-3 cm ngobukhulu enqubweni yokukhipha i-pancreatic head. Ukuhlolwa kwezifo kuqinisekisile ukuthi i-adenocarcinoma yayihlukaniswe ngokulingene. Ngemva kokuhlinzwa, sathola i-paclitaxel (nab-paclitaxel) eboshwe nge-albumin ehlanganiswe ne-S-1 chemotherapy, kwalandela i-M108 + nab-paclitaxel + gemcitabine kanye ne-LM108 ehlanganiswe ne-toripalimab. Sasinomlando we-schizophrenia kanye nesifo sikashukela, kokubili okulawulwa kahle ngemithi.
NgoFebhuwari 2025, isiguli sathola ukumnika amaseli e-KD-496 CAR-T. Ekuhlolweni kokuqala kwesimila ngemva kwamasonto amane, naphezu kokuguga kwaso kanye nomthwalo omkhulu wesimila (isilonda esiyisisekelo esingu-58 mm), isilonda esiqondiwe sase sinciphe ngo-34.5% kusukela ekuqaleni. Ngosuku lwama-60, isilonda esiqondiwe sase sinciphe ngo-37.9%, kwathi ngosuku lwama-90 no-180, isimila saqhubeka nokuncipha ngo-44.8%, sigcina impendulo engaphelele (PR) ngaphandle kobuthi obukhulu besisu noma bemizwa.
Isiguli esineminyaka engu-70 ubudala esinomdlavuza wesisu sahlinzwa ngoFebhuwari 2023, lapho i-pathology yangemva kokuhlinzwa iveza i-adenocarcinoma enesilonda esilinganiselwe kuya kwesingacacile kahle esasivele sisakazeke kuma-lymph nodes, i-peritoneum, kanye namaphaphu womabili, ehambisana ne-ascites kanye ne-pleural effusion (isifo esithuthukisiwe, esisakazeke kakhulu). Emasontweni ayisishiyagalombili ngemuva kokuhlinzwa, wathola i-SOX chemotherapy (i-oxaliplatin + S-1), kodwa isimo sakhe saqhubeka. Imizamo elandelayo nge-PX (paclitaxel) + PD-1 (immunotherapy) imijikelezo emine, elandelwa yi-capecitabine + nivolumab, nayo yehlulekile ukumisa ukuqhubeka. Ekugcineni, i-nivolumab + fruquintinib (umuthi wokulwa ne-angiogenic) yanikezwa, kodwa ngempumelelo elinganiselwe.
Ngosuku lwama-28 lokwelashwa kwe-CAR-T, isimila sase sinciphe ngo-47.3% uma kuqhathaniswa nokwelashwa kwangaphambi kokwelashwa, kwatholakala impendulo ejulile engaphelele (PR). Ngosuku lwama-60, isimila saqhubeka nokuncipha ngo-41.9%, sigcina i-PR eqinisekisiwe, okubonisa ukwelashwa okuqhubekayo nokusebenzayo.
Isiguli esineminyaka engu-55 ubudala esinomdlavuza wesisu senziwa i-laparoscopic radical gastrectomy ngoNovemba 2023, kanti i-pathology yangemva kokuhlinzwa yabonisa i-adenocarcinoma engahlukani kahle ne-partial signet-ring cell carcinoma (eyingozi kakhulu). Wazama izindlela eziningi zokwelashwa ngamakhemikhali + i-immunotherapy, okuhlanganisa i-oxaliplatin + capecitabine + sintilimab, i-oxaliplatin + leucovorin + sintilimab, i-nab-paclitaxel + sintilimab + fruquintinib, kanye ne-irinotecan monotherapy. Kodwa-ke, ngoFebhuwari 2025, isimo sakhe sathuthuka ngokushesha, okwenza ukwelashwa okuvamile kungasebenzi.
Wabe esethola ukwelashwa ngamaseli e-CAR-T, kwathi ngosuku lwama-28, isimila sase sinciphe ngo-31.8% uma kuqhathaniswa nokwelashwa kwangaphambi kokwelashwa, kwatholakala impendulo engaphelele (PR), kanti ukulawulwa kwesifo kufezwe ngempumelelo.
Njengamanje, kusenezivivinyo eziningi zemitholampilo zobuchwepheshe obusha bokulwa nomdlavuza eShayina ezifuna iziguli. Ukubonisana ngemithi emisha kanye nobuchwepheshe, ungaxhumana noMnyango Wezizwe Ngezizwe Wesibhedlela iBeijing South Region Oncology.
Inombolo yocingo: 4008803716
I-ID ye-WeChat: 17801183037
I-imeyili：myimmnet@163.com
Isikhathi sokuthunyelwe: Julayi-31-2025